Cargando…

Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase III high‐risk B acute lymphoblastic leukemia trial AALL0232

The Children's Oncology Group (COG) develops and implements multi‐institutional clinical trials with the primary goal of assessing the efficacy and safety profile of treatment regimens for various pediatric cancers. However, the monetary costs of treatment regimens are not measured. AALL0232 wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	DiNofia, Amanda M., Seif, Alix E., Devidas, Meenakshi, Li, Yimei, Hall, Matthew, Huang, Yuan‐Shung V., Cahen, Viviane, Hunger, Stephen P., Winick, Naomi J., Carroll, William L., Fisher, Brian T., Larsen, Eric C., Aplenc, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773964/ https://www.ncbi.nlm.nih.gov/pubmed/29274118 http://dx.doi.org/10.1002/cam4.1206

Ejemplares similares

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States
por: DiNofia, Amanda M., et al.
Publicado: (2016)

Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
por: Guest, Erin M., et al.
Publicado: (2022)

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433
por: Lew, Glen, et al.
Publicado: (2020)

Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group
por: Salzer, Wanda L., et al.
Publicado: (2009)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

EHMTI-0232. Non-surgical management of rhinogenic contact point headache
por: Roozbahany, N Ahmady, et al.
Publicado: (2014)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL
por: DiNofia, Amanda M., et al.
Publicado: (2019)

Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia
por: Yang, Wenjian, et al.
Publicado: (2022)

0232. Evaluation of HFNC'S wash out effect; a comparison of open- and closed-mouth models
por: Nakamura, N, et al.
Publicado: (2014)

Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia
por: Getz, Kelly D., et al.
Publicado: (2018)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia
por: Getz, Kelly D, et al.
Publicado: (2015)

SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731
por: Elgarten, Caitlin W., et al.
Publicado: (2023)

Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2017)

Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report
por: Gaynon, Paul S., et al.
Publicado: (2009)

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
por: Burke, Michael J., et al.
Publicado: (2019)

Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database
por: Citrin, Rebecca, et al.
Publicado: (2017)

P02.32. Complementing the homeostasis model by a Rhythm Model – a conceptual framework to understand non-pharmacological complementary therapies
por: Cysarz, D, et al.
Publicado: (2012)

Predicting psychiatric inpatient costs
por: Sabes-Figuera, Ramon, et al.
Publicado: (2015)

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
por: Urtishak, Karen A., et al.
Publicado: (2018)

Measuring inpatient and outpatient costs: A cost-function approach
por: Carey, Kathleen, et al.
Publicado: (1992)

Prevalence and cost of imaging in inpatient falls: the rising cost of falling
por: Fields, Jessica, et al.
Publicado: (2015)

The effects of patient cost sharing on inpatient utilization, cost, and outcome
por: Xu, Yuan, et al.
Publicado: (2017)

A Strategy to Reduce Heart Failure Readmissions and Inpatient Costs
por: Howie-Esquivel, Jill, et al.
Publicado: (2015)

Cost of Inpatient Falls and Cost-Benefit Analysis of Implementation of an Evidence-Based Fall Prevention Program
por: Dykes, Patricia C., et al.
Publicado: (2023)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

Correction: The effects of patient cost sharing on inpatient utilization, cost, and outcome
por: Xu, Yuan, et al.
Publicado: (2018)

Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia
por: Escherich, Carolin, et al.
Publicado: (2022)

Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children
por: Escherich, Carolin, et al.
Publicado: (2023)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Cost analysis of UMMC services: estimating the unit cost for outpatient and inpatient services
por: Dahlui, Maznah, et al.
Publicado: (2012)

Determinants of Hospital Inpatient Costs in the Iranian Elderly: A Micro-costing Analysis
por: Hazrati, Ebrahim, et al.
Publicado: (2020)

Costs structure of the inpatient ischemic stroke treatment using an exact costing method
por: Puumalainen, Anne, et al.
Publicado: (2020)

Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children
por: Xu, Heng, et al.
Publicado: (2015)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Why is the inpatient cost of dying increasing in India?
por: Das, Sumit Kumar, et al.
Publicado: (2018)

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
por: Schuelke, Matthew R., et al.
Publicado: (2023)

KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children’s Oncology Group P9407 trial study
por: Robinson, Blaine W., et al.
Publicado: (2023)

JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia
por: Bodaar, Kimberly, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ds9h71qvetv6i0h4c9ocshmt6